Empliciti

 

Topic mentions per year

Topic mentions per year

2016-2016
02420162016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
On November 30, 2015, the FDA approved elotuzumab (Empliciti; Bristol-Myers Squibb) in combination with lenalidomide and… (More)
Is this relevant?
Review
2017
Review
2017
CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also… (More)
Is this relevant?
Review
2016
Review
2016
129 The biopharmaceutical industry enjoyed continued regulatory momentum in 2015 as an historically efficient US Food and Drug… (More)
  • figure 1
  • table 1
Is this relevant?
Review
2016
Review
2016
VOLUME 34 NUMBER 2 FEBRUARY 2016 NATURE BIOTECHNOLOGY on three types of approaches. One takes aim at the cell’s ability to… (More)
Is this relevant?
2016
2016
• Elotuzumab (Empliciti) is a new monoclonal antibody approved to treat multiple myeloma in combination with lenalidomide… (More)
Is this relevant?
Review
2016
Review
2016
© 2016 Harborside Press® Multiple myeloma (MM) is a hematologic cancer in which malignant plasma cells are formed. Plasma cells… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?